The core operational beat (ex-CMS benefit) was solid but not spectacular — 17% net sales growth and 7% Jakafi growth are in line with prior trends. The raised sales guidance is positive, but the massive expense guidance increase from the Vega acquisition will compress near-term GAAP earnings. Watch for the Q3 2026 IPRD charge (~$1.27B) which will create a large GAAP earnings miss, and monitor pipeline catalysts (povorcitinib HS approval, Monjuvi DLBCL launch) for the real value drivers. The stock may initially rally on the headline beat and raised guidance, but the one-time nature of the CMS benefit and the expense overhang suggest limited sustained upside.
Price Chart
Executive Summary
Incyte reported Q2 2026 GAAP diluted EPS of $2.81 (vs consensus $2.15, +30.7% beat) and total revenue of $1.67B (vs consensus $1.49B, +12.1% beat), driven by a $246M one-time non-cash benefit from a CMS settlement on Opzelura. Excluding that benefit, total net sales grew 17% YoY. The company raised full-year total net sales guidance to $5.13B-$5.26B (from $4.77B-$4.94B) and Opzelura guidance to $1.05B-$1.10B, but also raised operating expense guidance sharply to reflect a $1.27B IPRD charge from the Vega Therapeutics acquisition. The core business (Jakafi +7%, Heme/Onc +69%) is solid, but the headline beat is heavily inflated by a one-time item, and the massive expense guidance increase clouds the forward earnings picture. The stock will likely trade on the raised sales guidance and pipeline progress, but the non-recurring nature of the CMS benefit tempers the bullish read-through for sustainable earnings power.
Key Financial Metrics
Key Facts
- Q2 2026 GAAP diluted EPS $2.81 vs consensus $2.15 (beat by 30.7%)
- Q2 2026 total revenue $1.67B vs consensus $1.49B (beat by 12.1%)
- Total net sales $1.49B, +40% YoY, but includes $246M one-time non-cash CMS settlement benefit; ex-benefit, net sales grew 17% YoY
- Jakafi/Jakafi XR net sales $817M, +7% YoY; Opzelura net sales $450M, +173% YoY (ex-benefit +24%)
- Raised FY2026 total net sales guidance to $5.13B-$5.26B from $4.77B-$4.94B
- Raised FY2026 GAAP R&D and SG&A expense guidance to $4.915B-$4.995B from $3.495B-$3.675B, reflecting ~$1.27B IPRD charge from Vega Therapeutics acquisition
- Completed acquisition of Vega Therapeutics for $1.25B upfront, adding latarcibart (Phase 3 for von Willebrand disease)
- Cash, cash equivalents and marketable securities $4.5B as of June 30, 2026
Financial Impact
Q2 revenue beat consensus by ~$180M, but $246M of that is a one-time non-cash benefit. Raised FY sales guidance by ~$360M at midpoint, but FY GAAP operating expense guidance raised by ~$1.37B at midpoint due to Vega IPRD charge.
Risk Factors
- $1.27B IPRD charge in Q3 2026 from Vega acquisition will create a large GAAP earnings miss
- Opzelura CMS settlement is a one-time benefit — core Opzelura growth ex-benefit was 24%, not 173%
- R&D spend continues to rise (+4% YoY) with 10 Phase 3 studies underway, pressuring margins
- INCB160058 (JAK2V617F) discontinued, removing a pipeline asset
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000879169-26-000053 |
| Document: incy-20260728.htm | 0000879169-26-000053 |
| Document: 0000879169-26-000053-index-headers.html | 0000879169-26-000053 |
| Document: 0000879169-26-000053-index.html | 0000879169-26-000053 |
| Document: 0000879169-26-000053.txt | 0000879169-26-000053 |
| 8-K Data (Synthetic) | 0000879169-26-000053 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Insider Cluster | $120.16 $122.19 | ▼ −1.69% | ▼ −3.68% | $115.06 (+4.24%) |
Aug 7, 2026 7w ago | Insider Cluster | $121.55 $124.40 | ▲ +2.34% | ▲ +3.26% | $115.06 (−5.34%) |
Aug 4, 2026 8w ago | Insider Cluster | $120.60 $124.50 | ▲ +3.23% | ▲ +4.47% | $115.06 (−4.59%) |
Jul 28, 2026 9w ago | 8-K | $129.93 $129.72 | ▼ −0.16% | ▼ −3.54% | $115.06 (−11.44%) |
Jul 20, 2026 10w ago | Insider Cluster | $115.65 $123.50 | ▲ +6.79% | ▲ +2.67% | $115.06 (−0.51%) |
Jul 20, 2026 10w ago | Insider Cluster | $115.65 $123.50 | ▲ +6.79% | ▲ +2.67% | $115.06 (−0.51%) |
Jun 8, 2026 16w ago | 8-K | $100.64 $115.62 | ▲ +14.88% | ▲ +13.25% | $115.06 (+14.33%) |
May 27, 2026 18w ago | DEFA14A | $97.26 $108.46 | ▲ +11.52% | ▲ +13.82% | $115.06 (+18.31%) |
Feb 28, 2026 30w ago | Institutional Cluster | $99.73 $90.31 | ▼ −9.45% | ▼ −1.51% | $115.06 (+15.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access